UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2020
Commission File Number:001-38281
ERYTECH Pharma S.A.
(Translation of registrant’s name into English)
60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ONFORM 6-K
Press Release
On June 9, 2020, Erytech Pharma S.A. (the “Company”) issued a press release regarding an update of its Phase 2 investigator sponsored trial of eryaspase for the treatment of second-line acute lymphoblastic leukemia patients. A copy of the press release is attached to this Report on Form6-K as Exhibit 99.1.
EXHIBITS
Exhibit | Description | |
99.1 | Press Release dated June 9, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ERYTECH Pharma S.A. | ||||||||
Date: June 9, 2020 | By: | /s/ Eric Soyer | ||||||
Name | Eric Soyer | |||||||
Title: | Chief Financial Officer and Chief Operating Officer |